Barclays
RNTX

Barclays’s Rein Therapeutics RNTX Stock Holding History

Barclays’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,264
Closed -$26K – 4818
2021
Q3 		$26K Buy
1,264
+887
+235% +$19.4K ﹤0.01% 4325
2021
Q2 		$9K Sell
377
-205
-35% -$5.12K ﹤0.01% 4682
2021
Q1 		$17K Buy
+582
New +$19.9K ﹤0.01% 4395
2019
Q4 		– Sell
-4
Closed – – 6887
2019
Q3 		$0 Buy
+4
New +$55 ﹤0.01% 7203
2018
Q2 		– Sell
-57
Closed -$9K – 7351
2018
Q1 		$9K Buy
57
+27
+90% +$4.81K ﹤0.01% 6695
2017
Q4 		$6K Buy
30
+24
+400% +$5.75K ﹤0.01% 6646
2017
Q3 		$2K Buy
+6
New +$1.5K ﹤0.01% 6698

Other funds holding RNTX

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KL
KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Barclays's RNTX Position: Q4 2021 in Review

Barclays sold out of Rein Therapeutics (RNTX) in Q4 2021, closing a stake of 1,264 shares — an estimated $26K sold.

Barclays first reported a position in RNTX in Q3 2017 and held it in 7 quarters. The position peaked at $26K in Q3 2021. 43 funds tracked by Wall St. Rank hold RNTX as of Q4 2021.

  • Barclays reported no remaining Rein Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Barclays sold 1,264 Rein Therapeutics shares in Q4 2021, an estimated $26K.
  • Barclays first reported a position in Rein Therapeutics in Q3 2017 and held it in 7 quarters.
  • Barclays's Rein Therapeutics position peaked at $26K in Q3 2021.
  • 43 funds tracked by Wall St. Rank held Rein Therapeutics as of Q4 2021.

Based on Barclays's 13F filing for Q4 2021, filed 14 Feb 2022.